Most biotech companies have a blog. Almost none of them have a content engine. The difference is structural — and it's the reason most biotech content efforts quietly die after 18 months.
A blog is a graveyard. It's where good ideas go to be published once, get 47 LinkedIn impressions, and disappear into the SEO void. A content engine is a compounding asset. It's a system that turns one founder insight into 30 distribution moments — and gets stronger every quarter.
What's actually wrong with the biotech blog
The pattern is familiar. The CMO commissions a blog. The first three posts go up with a flourish. Then someone notices that the blog isn't generating leads, the founder is too busy to write more, and within a year the latest post is "Happy New Year 2024" sitting awkwardly at the top of a dusty page.
This isn't a content problem. It's a system problem. A blog has no compounding mechanism. Every post starts at zero. Every post requires the same effort as the last one. Nothing in the architecture forces leverage.
What a content engine actually looks like
A content engine has three characteristics that a blog does not:
1. Pillar content with downstream artifacts
Every "primary" piece of content (a whitepaper, a long-form article, a recorded interview) gets systematically broken down into 8-12 secondary artifacts: LinkedIn posts, X threads, newsletter sections, sales enablement one-pagers, conference deck content. One unit of effort produces dozens of distribution moments.
2. A repeatable production rhythm
The engine doesn't depend on heroics. It runs on a cadence: monthly founder interview, biweekly long-form publication, weekly distribution sprint. When the founder is busy (always), the engine doesn't stop — it draws from a backlog of insights captured in earlier sessions.
3. Compounding assets, not one-time posts
Content built for the engine is designed to be re-surfaced. Evergreen explainers. Founder POVs that age well. Case studies that get cited for years. The library appreciates over time, like a well-managed patent portfolio.
A blog asks "what should we write this month?" An engine asks "how do we extract maximum leverage from what the founder already thinks?"
The minimum viable engine
You don't need a 12-person content team. The minimum viable biotech content engine looks like this:
- One 60-min monthly founder session — recorded, transcribed, mined for the next 30 days of content
- One long-form piece per month — derived from the session, scientifically reviewed, indexed for SEO and AI search
- 8-12 social posts per month — extracted from the long-form, distributed across LinkedIn and X
- One quarterly anchor asset — whitepaper, case study, or industry report that becomes a sales weapon
That's it. Done well, this beats a 5-person in-house content team that's reactive, scattered, and writing for everyone.
Why most biotechs won't build this
Because it requires admitting that "we'll just have the marketing person write some blog posts" was never going to work. It requires the founder to commit to a monthly hour. It requires structure where most biotechs prefer activity.
The biotechs that do build it accumulate an unfair advantage. Two years in, their content library is impossible to replicate. Their founder is the recognized voice in their category. Their inbound pipeline is full.
The biotechs that don't build it are still asking, three years from now, why their competitor — with worse science — keeps closing rounds first.